Inocras Inc. published a new study in npj Precision Oncology showing that Whole Genomic Profiling (WGS) can uncover clinically relevant genomic alterations in metastatic prostate cancer compared to targeted panels.

Inocras is a bioinformatics-led company redefining precision health through whole genome data and proprietary analytics. Our oncology and rare disease platforms integrate comprehensive whole genome data with advanced automation to deliver curated and actionable insights at scale. These capabilities deliver curated, actionable insights that accelerate discovery and diagnostics to improve patient care, bringing a real-world impact. We operate a CLIA/CAP-certified laboratory and partners with leading hospitals, pharmaceutical companies, and research institutions worldwide.